MGMoritz Gross

Moritz Gross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Moritz Gross has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • John A. Onofrey

    Department of Radiology and Biomedical Imaging, the Department of Biomedical Engineering, and the Department of Electrical and Computer Engineering, Yale University, New Haven, CT, USA

    5 shared publications
  • Ahmet S. Kucukkaya

    Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, USA

    4 shared publications
  • Bernhard Gebauer

    Department of Radiology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, 13353 Berlin, Germany

    4 shared publications
  • Julius Chapiro

    Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; Department of Biomedical Engineering, Yale University, New Haven, Connecticut; Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut

    4 shared publications
  • Julius Chapiro

    Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT, 06520, USA; Department of Biomedical Engineering, School of Engineering and Applied Sciences, 17 Hillhouse Avenue, New Haven, CT, 06520, USA; Department of Medicine, Liver Center, Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar St, New Haven, CT, 06520, USA

    4 shared publications
  • Simon Iseke

    Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, USA

    4 shared publications

Latest Publications

  • Open Access

    Deep learning-based generation of synthetic multiphasic MRI in hepatocellular carcinoma and cirrhosis

    by Sara A. Abosabie, Salma A.S. Abosabie, Weicheng Dai, Junlin Yang, Moritz Gross, Jeffrey Weinreb, Margarita V. Revzin, Gaurav Parmar, Chenyu You, MingDe Lin, et al.


  • Noninvasive Tumor Profiling: Quantitative Contrast-enhanced MRI Markers Help Predict PD-L1 and CTNNB1 Status in Hepatocellular Carcinoma

    by Nickolai J. Matuschewski, Rabea Sobirey, Margarita Revzin, Tal Zeevi, Moritz Gross, Victor Kasolowsky, Annabella Shewarega, Ellen Meister, Tabea Kao, Jonathan Tefera, et al.

    Quantitative multiparametric contrast-enhanced MRI parameters helped predict molecular profiles of hepatocellular carcinoma via machine learning algorithms.


  • Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases

    by Tom N. Kuhn, William D. Engelhardt, Vinzent H. Kahl, Abedalrazaq Alkukhun, Moritz Gross, Simon Iseke, John Onofrey, Anne Covey, Juan C. Camacho, Yoshikuni Kawaguchi, et al.


  • Open Access

    Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning

    by Moritz Gross, Stefan P. Haider, Tal Ze’eVi, Steffen Huber, Sandeep Arora, Ahmet S. Kucukkaya, Simon Iseke, Bernhard Gebauer, Florian Fleckenstein, Marc Dewey, et al.

    Background: Accurate mortality risk quantification is crucial for the management of hepatocellular carcinoma (HCC); however, most scoring systems are subjective. Purpose: To develop and independently validate a machine learning mortality risk quantification method for HCC patients using standard-of-care clinical data and liver radiomics on baseline magnetic resonance imaging (MRI). Methods: This retrospective study included all patients with multiphasic contrast-enhanced MRI at the time of diagnosis treated at our institution. Patients were censored at their last date of follow-up, end-of-observation, or liver transplantation date. The data were randomly sampled into independent cohorts, with 85% for development and 15% for independent validation. An automated liver segmentation framework was adopted for radiomic feature extraction. A random survival forest combined clinical and radiomic variables to predict overall survival (OS), and performance was evaluated using Harrell’s C-index. Results: A total of 555 treatment-naïve HCC patients (mean age, 63.8 years ± 8.9 [standard deviation]; 118 females) with MRI at the time of diagnosis were included, of which 287 (51.7%) died after a median time of 14.40 (interquartile range, 22.23) months, and had median followed up of 32.47 (interquartile range, 61.5) months. The developed risk prediction framework required 1.11 min on average and yielded C-indices of 0.8503 and 0.8234 in the development and independent validation cohorts, respectively, outperforming conventional clinical staging systems. Predicted risk scores were significantly associated with OS (p < .00001 in both cohorts). Conclusions: Machine learning reliably, rapidly, and reproducibly predicts mortality risk in patients with hepatocellular carcinoma from data routinely acquired in clinical practice. Clinical relevance statement: Precision mortality risk prediction using routinely available standard-of-care clinical data and automated MRI radiomic features could enable personalized follow-up strategies, guide management decisions, and improve clinical workflow efficiency in tumor boards. Key Points: • Machine learning enables hepatocellular carcinoma mortality risk prediction using standard-of-care clinical data and automated radiomic features from multiphasic contrast-enhanced MRI. • Automated mortality risk prediction achieved state-of-the-art performances for mortality risk quantification and outperformed conventional clinical staging systems. • Patients were stratified into low, intermediate, and high-risk groups with significantly different survival times, generalizable to an independent evaluation cohort.


  • Open Access

    Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics

    by Moritz Gross, Steffen Huber, Sandeep Arora, Tal Ze’eVi, Stefan P. Haider, Ahmet S. Kucukkaya, Simon Iseke, Tom Niklas Kuhn, Bernhard Gebauer, Florian Michallek, et al.

    Objectives: To develop and evaluate a deep convolutional neural network (DCNN) for automated liver segmentation, volumetry, and radiomic feature extraction on contrast-enhanced portal venous phase magnetic resonance imaging (MRI). Materials and methods: This retrospective study included hepatocellular carcinoma patients from an institutional database with portal venous MRI. After manual segmentation, the data was randomly split into independent training, validation, and internal testing sets. From a collaborating institution, de-identified scans were used for external testing. The public LiverHccSeg dataset was used for further external validation. A 3D DCNN was trained to automatically segment the liver. Segmentation accuracy was quantified by the Dice similarity coefficient (DSC) with respect to manual segmentation. A Mann-Whitney U test was used to compare the internal and external test sets. Agreement of volumetry and radiomic features was assessed using the intraclass correlation coefficient (ICC). Results: In total, 470 patients met the inclusion criteria (63.9±8.2 years; 376 males) and 20 patients were used for external validation (41±12 years; 13 males). DSC segmentation accuracy of the DCNN was similarly high between the internal (0.97±0.01) and external (0.96±0.03) test sets (p=0.28) and demonstrated robust segmentation performance on public testing (0.93±0.03). Agreement of liver volumetry was satisfactory in the internal (ICC, 0.99), external (ICC, 0.97), and public (ICC, 0.85) test sets. Radiomic features demonstrated excellent agreement in the internal (mean ICC, 0.98±0.04), external (mean ICC, 0.94±0.10), and public (mean ICC, 0.91±0.09) datasets. Conclusion: Automated liver segmentation yields robust and generalizable segmentation performance on MRI data and can be used for volumetry and radiomic feature extraction. Clinical relevance statement: Liver volumetry, anatomic localization, and extraction of quantitative imaging biomarkers require accurate segmentation, but manual segmentation is time-consuming. A deep convolutional neural network demonstrates fast and accurate segmentation performance on T1-weighted portal venous MRI. Key Points: • This deep convolutional neural network yields robust and generalizable liver segmentation performance on internal, external, and public testing data. • Automated liver volumetry demonstrated excellent agreement with manual volumetry. • Automated liver segmentations can be used for robust and reproducible radiomic feature extraction.


  • Open Access

    LiverHccSeg: A publicly available multiphasic MRI dataset with liver and HCC tumor segmentations and inter-rater agreement analysis

    by Moritz Gross, Sandeep Arora, Steffen Huber, Ahmet S. Kücükkaya, John A. Onofrey


  • MR Imaging–Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver

    by Jessica G. Santana, Alexandra Petukhova-Greenstein, Moritz Gross, Fahmeed Hyder, Vasily Pekurovsky, Luzie A. Gottwald, Annemarie Boustani, John J. Walsh, Ahmet S. Kucukkaya, Rohil Malpani, et al.


  • Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model

    by Antonia M. Berz, Jessica G. Santana, Simon Iseke, Moritz Gross, Vasily Pekurovsky, Fabian Laage Gaupp, Lynn J. Savic, Tabea Borde, Luzie A. Gottwald, Anne Marie Boustani, et al.


  • Open Access

    Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging

    by Moritz Gross, Michael Spektor, Ariel Jaffe, Ahmet S. Kucukkaya, Simon Iseke, Stefan P. Haider, Mario Strazzabosco, Julius Chapiro, John A. Onofrey

    Purpose: Accurate liver segmentation is key for volumetry assessment to guide treatment decisions. Moreover, it is an important pre-processing step for cancer detection algorithms. Liver segmentation can be especially challenging in patients with cancer-related tissue changes and shape deformation. The aim of this study was to assess the ability of state-of-the-art deep learning 3D liver segmentation algorithms to generalize across all different Barcelona Clinic Liver Cancer (BCLC) liver cancer stages. Methods: This retrospective study, included patients from an institutional database that had arterial-phase T1-weighted magnetic resonance images with corresponding manual liver segmentations. The data was split into 70/15/15% for training/validation/testing each proportionally equal across BCLC stages. Two 3D convolutional neural networks were trained using identical U-net-derived architectures with equal sized training datasets: one spanning all BCLC stages (“All-Stage-Net": AS-Net), and one limited to early and intermediate BCLC stages (“Early-Intermediate-Stage-Net": EIS-Net). Segmentation accuracy was evaluated by the Dice Similarity Coefficient (DSC) on a dataset spanning all BCLC stages and a Wilcoxon signed-rank test was used for pairwise comparisons. Results: 219 subjects met the inclusion criteria (170 males, 49 females, 62.8±9.1 years) from all BCLC stages. Both networks were trained using 129 subjects: AS-Net training comprised 19, 74, 18, 8, and 10 BCLC 0, A, B, C, and D patients, respectively; EIS-Net training comprised 21, 86, and 22 BCLC 0, A, and B patients, respectively. DSCs (mean±SD) were 0.954±0.018 and 0.946±0.032 for AS-Net and EIS-Net (p<0.001), respectively. The AS-Net 0.956±0.014 significantly outperformed the EIS-Net 0.941±0.038 on advanced BCLC stages (p<0.001) and yielded similarly good segmentation performance on early and intermediate stages (AS-Net: 0.952±0.021; EIS-Net: 0.949±0.027; p = 0.107). Conclusion: To ensure robust segmentation performance across cancer stages that is independent of liver shape deformation and tumor burden, it is critical to train deep learning models on heterogeneous imaging data spanning all BCLC stages.


  • Admission computed tomography radiomic signatures outperform hematoma volume in predicting baseline clinical severity and functional outcome in the ATACH‐2 trial intracerebral hemorrhage population

    by Stefan P. Haider, Adnan I. Qureshi, Abhi Jain, Hishan Tharmaseelan, Elisa R. Berson, Tal Zeevi, Shahram Majidi, Christopher G. Filippi, Simon Iseke, Moritz Gross, et al.

    Background and purpose: Radiomics provides a framework for automated extraction of high‐dimensional feature sets from medical images. We aimed to determine radiomics signature correlates of admission clinical severity and medium‐term outcome from intracerebral hemorrhage (ICH) lesions on baseline head computed tomography (CT).Methods: We used the ATACH‐2 (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) trial dataset. Patients included in this analysis (n = 895) were randomly allocated to discovery (n = 448) and independent validation (n = 447) cohorts. We extracted 1130 radiomics features from hematoma lesions on baseline noncontrast head CT scans and generated radiomics signatures associated with admission Glasgow Coma Scale (GCS), admission National Institutes of Health Stroke Scale (NIHSS), and 3‐month modified Rankin Scale (mRS) scores. Spearman's correlation between radiomics signatures and corresponding target variables was compared with hematoma volume.Results: In the discovery cohort, radiomics signatures, compared to ICH volume, had a significantly stronger association with admission GCS (0.47 vs. 0.44, p = 0.008), admission NIHSS (0.69 vs. 0.57, p < 0.001), and 3‐month mRS scores (0.44 vs. 0.32, p < 0.001). Similarly, in independent validation, radiomics signatures, compared to ICH volume, had a significantly stronger association with admission GCS (0.43 vs. 0.41, p = 0.02), NIHSS (0.64 vs. 0.56, p < 0.001), and 3‐month mRS scores (0.43 vs. 0.33, p < 0.001). In multiple regression analysis adjusted for known predictors of ICH outcome, the radiomics signature was an independent predictor of 3‐month mRS in both cohorts.Conclusions: Limited by the enrollment criteria of the ATACH‐2 trial, we showed that radiomics features quantifying hematoma texture, density, and shape on baseline CT can provide imaging correlates for clinical presentation and 3‐month outcome. These findings couldtrigger a paradigm shift where imaging biomarkers may improve current modelsfor prognostication, risk‐stratification, and treatment triage of ICH patients.